Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2089471 | Journal of Immunological Methods | 2006 | 10 Pages |
Abstract
Methamphetamine and ecstasy are addictive drugs that cause major health problems in young people. Here we report on the development of high-affinity monoclonal antibodies to methamphetamine and its analogues, which may constitute powerful tools for antibody-based therapy. Six haptens, methamphetamine and ecstasy analogues, were synthesized, linked to a carrier protein and injected into mice. Several specific monoclonal antibodies were subsequently obtained following fusion of splenocytes from the immunized animals, with Sp2/O cells. Antibody specificity was fully investigated by competition ELISA, using a series of analogues, to identify specific amphetamine and/or ecstasy-specific antibodies. Antibody affinity was estimated to be in the range of 108 Mâ 1 with an enantiomeric hapten. Finally, two characteristic hybridoma clones (DAS-M243-6 H5 and DAS-M278-4 B12), secreting specific and potent mAbs were isolated. The development of drug-specific antibodies as in this study may provide promising therapeutic insight into how to neutralize methamphetamine in vivo during acute intoxication.
Keywords
DCCBOCRIATFAN-hydroxysuccinimidedicyclohexylcarbodiimideKLHmAbsTBSNHSSMCCTHFStereospecificityEDCIgGmAbdi-tert-butyl dicarbonatePBSHOBt1-hydroxybenzotriazoleBSAPd/Cbovine serum albuminMonoclonal antibodyTrifluoroacetic acidEcstasyimmunoglobulin GTris-buffered salineELISAEnzyme-linked immunosorbent assaytetanus toxoidCNSradioimmunoassaycentral nervous systemMethamphetaminePhosphate-buffered salineAffinityPalladium on carbonoptical densitykeyhole limpet hemocyanin
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Yannic Danger, Caroline Gadjou, Anne Devys, Hervé Galons, Dominique Blanchard, Gilles Folléa,